AstraZenecaSTU:ZEGA +1.30%87 PEG Ratio is 2.53 as of Jul. 08, 2026, which is 68% below its 10-year median of 8.03. GuruFocus rates STU:ZEGA with a GF Score™ of 87/100 and a GF Value™ of €73.02. The stock has 5 warning signs investors should review. Among 350 Drug Manufacturers companies, AstraZeneca ranks better than 58.86% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, AstraZeneca's PE Ratio without NRI is 56.89. AstraZeneca's 5-Year EBITDA growth rate is 22.50%. Therefore, AstraZeneca's PEG Ratio for today is 2.53.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for AstraZeneca's PEG Ratio or its related term are showing as below:
STU:ZEGA'
s PEG Ratio Range Over the Past 10 Years
Min: 1.05 Med: 8.03 Max: 658.8
Current: 1.29
During the past 13 years, AstraZeneca's highest PEG Ratio was 658.80. The lowest was 1.05. And the median was 8.03.
STU:ZEGA's PEG Ratio is ranked better than 58.86% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.725
vs STU:ZEGA: 1.29
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
AstraZeneca (STU:ZEGA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
AstraZeneca PEG Ratio Related Terms
AstraZeneca PEG Ratio Historical Data
* Premium members only.
The historical data trend for AstraZeneca's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, AstraZeneca's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's PEG Ratio distribution charts can be found below:
* The bar in red indicates where AstraZeneca's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
AstraZeneca (STU:ZEGA) has a PEG Ratio of 2.53 as of Jul. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on AstraZeneca and its competitors. This is 68% below median its historical median of 8.03. Over the past decade, AstraZeneca's PEG Ratio has ranged from 1.05 to 658.80. According to the industry distribution chart, AstraZeneca ranks #144 out of 350 companies in the Drug Manufacturers industry, placing it in the top 41.1%.
Is AstraZeneca's PEG Ratio too high?
AstraZeneca's current PEG Ratio of 2.53 is 68% below median its 10-year median of 8.03. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 658.80. The Drug Manufacturers industry median PEG Ratio is 1.73. AstraZeneca's value of 2.53 is 46.7% above this industry median. Based on the distribution chart, AstraZeneca ranks #144 out of 350 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AstraZeneca has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's PEG Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #144 out of 350 companies for PEG Ratio. This puts AstraZeneca in the upper half of its industry. The industry median PEG Ratio is 1.73. AstraZeneca's value of 2.53 is 46.7% above this benchmark. Historically, AstraZeneca's own PEG Ratio has ranged from 1.05 to 658.80 over the past decade. While the company's 10-year median is 8.03 vs. the industry median of 1.73, AstraZeneca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.73, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca's current PEG Ratio of 2.53 is 46.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on AstraZeneca and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current PEG Ratio is 2.53, which is 68% below median its own 10-year median of 8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current PEG Ratio of 2.53. The stock's GF Value™ is €73.02, compared to a current price of €78.00 — trading 6.8% above its estimated fair value. The current PEG Ratio is 2.53, which is 68% below median its 10-year median of 8.03 and 46.7% above the Drug Manufacturers industry median of 1.73. AstraZeneca's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current PEG Ratio is 2.53 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (STU:ZEGA) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued.
The current stock price of €78.00 is trading 6.8% above its estimated GF Value™ of €73.02.
Key valuation signals for STU:ZEGA:
PEG Ratio: 2.53 (68% below median its 10-year median of 8.03)
GF Value™: €73.02 vs. price of €78.00 (6.8% above fair value)
Industry Position: 46.7% above the Drug Manufacturers median (#144 of 350)
No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score
Get the complete analysis for STU:ZEGA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZEGA has been successfully added to your 
